New appointment at Merck & Co
This article was originally published in Scrip
Executive Summary
Merck & Co has named Dr Michael Mendelsohn senior vice-president of Merck Research Laboratories and franchise head, atherosclerosis and cardiovascular research. He joins the company after 17 years at Tufts Medical Center in Boston. He was the founder and for twelve years the executive director of the Center's Molecular Cardiology Research Institute, and for the past two years served as the first chief scientific officer at Tufts. Dr Mendelsohn will be based at Merck's site in Rahway, New Jersey, and will report to the company's senior vice-president, global scientific strategy, Dr Luciano Rossetti.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.